News Report | November 18, 2018
UPMC Announces Value-Based Care Contract With Boehringer Ingelheim For Jardiance
On September 27, 2018, UPMC Health Plan announced it started a value-based contract with Boehringer Ingelheim for Jardiance, an oral medication to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. The contract goes live on January 1, 2019. The contract links reimbursement of the drug to costs associated with clinical outcomes among UPMC members who use Jardiance. Reimbursement for the medication will be linked to total costs of care for all people with diabetes treated. Previous contracts for Jardiance measured costs only in those with existing heart disease. UPMC Health Plan . . .